(Reuters) - Alexza Pharmaceuticals Inc resubmitted the marketing application for its anti-agitation treatment earlier than expected, sending its shares up as much as 47 percent.
Valeant Pharmaceuticals VRX announced Monday that its partner Alexza Pharmaceuticals ALXA received a complete response letter on drug candidate adusuve staccato (formerly known as staccato loxapine). We will maintain
We are no longer providing equity research on Alexza Pharmaceuticals ALXA . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Alexza Pharmaceuticals ALXA announced that it has exercised its option to purchase longtime partner Symphony Allegro in a deal expected to close in the third
Despite Alexza Pharmaceuticals ' ALXA success at narrowing its net loss for the first quarter, we are keeping our fair value estimate in place because of our continuing
We are putting Alexza Pharmaceuticals ALXA under review after the firm announced that it will reduce its workforce by 33% and halt certain early-stage drug-development
Alexza Pharmaceuticals ALXA announced positive results from its second Phase III trial of its lead antipsychotic drug, AZ-004, for treatment of acute agitation
We're lowering Alexza Pharmaceuticals ' ALXA fair value uncertainty rating. Although we believe the company still represents a very speculative investment, we don't feel
We're raising our fair value estimate uncertainty rating for Alexza Pharmaceuticals ALXA to extreme, as it is looking more likely that the firm will need to raise more funds before the end of 2009 to continue its development
On Wednesday, Alexza ALXA reported second-quarter results that were in line with our expectations. Therefore, we don't expect any changes to our fair